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Our ideology of current day life’s pathology is conceived as 
a linear process which is required to be improved
with regards to understanding of differing and evolving 
dogma of newer approach towards hypothesized
pathogenesis. The learning curve as we interpret today 
about the “dilemma of sweetness” i.e., diabetes mellitus is 
no more the way as we learnt over the last few
centuries [1]. Moving across the milestones of medical 
literacy supplanted by quality research and revolutionizing 
nano-technological advancements we are now able to 
dissect out the heterogeneity of the disease i.e. type-2 
diabetes mellitus (T2DM). Though the scientific data 
seems preliminary in its path to comprehension, still it has 
managed to lay down pointers in the evolving landscape of 
T2DM [2].
As we write about T2DM we had in our hindsight the
growing nature of this metabolic plague with current
prevalence racing to 451 million sufferers worldwide with 
next milestone peaking around 693 million by the year 
2045 [3]. There could be some discrepancies in exactness 
of the statistical calculations from Zhang et al., still the 
suggested yearly spending of 376 billion USD in 2010 to 
490 billion USD by 2030 among age 20-79 years group 
seem to an optimal depiction of this T2DM disease burden 
[4]. These statistical calculation will never be able to
calculate time lost from non-productivity, indirect spending 
to modify lifestyles and long-term financial loss form its 
complications. The myriad of complications tailed to T2DM 
are not just micro vascular diseases like neuropathy, 
retinopathy, nephropathy, but the real breakpoint for 
mankind remains coronary artery disease and stroke now 
surfacing as the world wide champions on mortality charts 
[5]. Considering the T2DM direct and indirect impacts
on health economy along with effects on quality of life
with related effects in the shape of atherosclerotic
cardiovascular disease (ASCVD), the pandemic now 
emerging as a Tsunami which can sweep the next
generations from this modern-day metabolic disaster [6].
Situation in third world population is even worse
resulting from the extremely rapid switch-over from
conventional “farmer’s way of life” to urbanized, being 
worst hit by environmental pollution and smog [7]. Ma et al. 
has termed the sub-continental population to have
“starvation genes” which cause their adipocytes to
accumulate extra fat making a mildly obese person to be 
vulnerable to cardiovascular diseases (CVD) [8].
Similarly, studies comparing sub-continental population 
from India, Pakistan and Bangladesh housing more than 
24% of people from the world indicate an extremely high 
population of diabetics with many yet to be diagnosed 
[9]. While a clear trend in this population is visible in 
terms of decreasing height and swollen tummies
bringing with it all possible metabolic curses including 
diabetes mellitus, there remains no denial for this 
diabetic problem swiftly taking over the hospitals and 
sucking the poor country’s economy in all possible ways 
[10]. Closing our eyes or living oblivious to this metabolic 
dilemma will only make the going gets tougher and may 
be disaster beyond human control.
 
The question arises what different we need to adopt to 
overcome this prevailing menace? With every challenge 
we face, there arises an area of opportunity. We not only 
need to understand the prevailing pathophysiology in 
terms of its epigenetic and genetic triggers inherent 
within our populace, but also define the preventive, 
therapeutic and rehabilitative measures to curb the 
surging Tsunami. Therefore any healthcare approach 
we select need not only to be wholesome but must 
remain compatible to the the health economy of our 
country of our country. While a complete panacea to this 
endemic may be utopian, the macro dimensions of the 
policy are suggested below:
a. Preventive medicine: The seed for this diseases 
roots within the life styles we adopt from our early life. 
“Health Education” is the key to parenting in terms of 
striking the much needed balance between starvation 
and overfeeding. While the mothers during pregnancy 
must adopt a regular healthy life inclusive of exercise 
with emphasis on prenatal screening of hyperglycemic 
tendencies, the newborn must not be overfed to 
suppress the growth hormone and other simulants to 
avoid early childhood obesity [11]. Education about 
metabolic disorders need to be started for early life as
a taught subject with more opportunities for physical 
activities. Two key recommendations may be to include
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“Sports” in student’s curriculum and the taxation may be 
enhanced on junk food. The later recommendation is 
essential as “Obesity is the new smoking” [12], where 
we already see tobacco products being injurious
to health are heavily taxed [13]. T2DM screening
strategies must be initiated at early childhood in terms of 
measuring fat mass, glucose screening and assessment 
of physical activity.
b. Therapeutic interventions: Multiple medicines are 
available to manage T2DM with race starting from 
sulphonylureas, metformin, PPAR-gamma agonists to 
the newly emerging competitors like DPP-IV inhibitors, 
GLP-1 agonists, amylin analogues and SGLT2 inhibitors 
[14]. However, these medications work primarily to 
reduce glucose and do not cure diabetes in anyway. 
Newer approaches mainly the bariatric surgery and 
sometimes pancreatic transplants are also now
marketed in many parts of the world with much success 
[15]. Very recently, biotechnology is emerging with
curative molecular genetic methods like CRISPR/Cas 
technologies, genome editing technologies, which 
though in research could still be one possibility to
revolutionize conventional anti-diabetic medicine [16]. 
Research in this area is warranted to root out diabetes at 
genetic level. 
c. Rehabilitative needs: There is mammoth diabetic 
population who are in need to be rehabilitated with 
updated and personalized evidence based rehabilitative 
medical specialist. Most patients getting the disease are 
not aware of the micro and macro vascular problems 
due to lack of focus on preventing T2DM complications 
and lifestyle advice. This aspect needs “centers for 
diabetes rehabilitation” along with enhancing qualified 
human resource with dialectology technicians, Nurses 
and medical dialectologists [17].
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